




??

????????????????????????????????

?????



????????????????



??????????



??????????

1. []

PPS ≥ 2

????????????????

I/S TDS RLD
TDS
I/S

??????????

TDS I/S

I/S " " TDS
21 14 17

TDS I/S

??????????

1.

TDS API I/S
TDS I/S
21 2 TDS
TDS TDS
TDS

2.

TDS I/S RLD
 $\leq 0.1\%$
RLD TDS TDS
I/S TDS TDS TDS

3.

167

[2] FDA. Assessing the Irritation and Sensitization Potential of Generic Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry [EB/OL]. Apr 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas>.

[3] EMA. Guideline on the pharmacokinetic and clinical evaluation of modified release 279 dosage forms [EB/OL]. Nov 2014. <https://www.ema.europa.eu/en/pharmacokinetic-clinical-evaluation-modified-release-dosage-forms-scientific-guideline>

[4] [REDACTED] . [REDACTED] [EB/OL]. 2022 [REDACTED] 5 [REDACTED] .

[5] [REDACTED] . [REDACTED] IVRT [REDACTED] IVPT [REDACTED] [EB/OL]. 2025 [REDACTED] 6 [REDACTED] .

[6] FDA. Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications [EB/OL]. Jul 2021. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-adhesion-topical-and-transdermal-systems-submitted-new-drug-applications>.

Revision #3

Created 2025-11-28 15:46:58 UTC by Colin Wang

Updated 2025-11-29 01:19:27 UTC by Colin Wang